Organigram Global (OGI) to Release Earnings on Tuesday

Organigram Global (NASDAQ:OGI) is expected to be releasing its Q1 2026 results before the market opens on Tuesday, February 10th. Analysts expect Organigram Global to post earnings of ($0.01) per share and revenue of $73.3780 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.

Organigram Global (NASDAQ:OGI) last released its quarterly earnings results on Tuesday, December 16th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.19). Organigram Global had a negative return on equity of 16.91% and a negative net margin of 9.99%.The business had revenue of $57.53 million during the quarter, compared to analyst estimates of $73.02 million. On average, analysts expect Organigram Global to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Global Price Performance

Organigram Global stock opened at $1.53 on Monday. The stock has a market capitalization of $206.75 million, a PE ratio of -13.91 and a beta of 1.60. The business has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.66. Organigram Global has a 12 month low of $0.85 and a 12 month high of $2.24.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Canaccord Genuity Group started coverage on shares of Organigram Global in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Wall Street Zen cut shares of Organigram Global from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Organigram Global in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Organigram Global

A number of large investors have recently made changes to their positions in OGI. Bank of America Corp DE lifted its position in Organigram Global by 1,678.1% during the third quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock worth $76,000 after buying an additional 35,256 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Organigram Global in the third quarter valued at about $907,000. Finally, Tidal Investments LLC increased its position in Organigram Global by 4.9% during the second quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock worth $3,573,000 after purchasing an additional 124,356 shares during the last quarter. 34.63% of the stock is currently owned by hedge funds and other institutional investors.

About Organigram Global

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.